Assembly dynamics of PML nuclear bodies in living cells by Brand, Peter et al.
RESEARCH ARTICLE Open Access
Assembly dynamics of PML nuclear bodies in
living cells
Peter Brand
1, Thorsten Lenser
2, Peter Hemmerich
1*
* Correspondence: phemmer@
fli-leibniz.de
1Leibniz-Institute of Age Research,
Fritz-Lipman-Institute,
Beutenbergstr, 11, 07745 Jena,
Germany
Abstract
The mammalian cell nucleus contains a variety of organelles or nuclear bodies which
contribute to key nuclear functions. Promyelocytic leukemia nuclear bodies (PML
NBs) are involved in the regulation of apoptosis, antiviral responses, the DNA
damage response and chromatin structure, but their precise biochemical function in
these nuclear pathways is unknown. One strategy to tackle this problem is to assess
the biophysical properties of the component parts of these macromolecular assem-
blies in living cells. In this study we determined PML NB assembly dynamics by live
cell imaging, combined with mathematical modeling. For the first time, dynamics of
PML body formation were measured in cells lacking endogenous PML. We show that
all six human nuclear PML isoforms are able to form nuclear bodies in PML negative
cells. All isoforms exhibit individual exchange rates at NBs in PML positive cells but
PML I, II, III and IV are static at nuclear bodies in PML negative cells, suggesting that
these isoforms require additional protein partners for efficient exchange. PML V turns
over at PML Nbs very slowly supporting the idea of a structural function for this iso-
form. We also demonstrate that SUMOylation of PML at Lysine positions K160 and/or
K490 are required for nuclear body formation in vivo.We propose a model in which
the isoform specific residence times of PML provide both, structural stability to
function as a scaffold and flexibility to attract specific nuclear proteins for efficient
biochemical reactions at the surface of nuclear bodies.
MCS code: 92C37
1 Background
The cell nucleus is functionally devoted to the realization and protection of the genetic
material it contains in the form of chromosome territories [1]. RNA transcription and
processing, DNA replication and DNA repair occur in a spatio-temporal coordinated
fashion in small, usually less than 100 nm large foci scattered throughout the nuclear
volume [2-4]. In addition, the mammalian cell nucleus contains a variety of internal
structures, also termed domains or bodies [5]. These macromolecular assemblies
include nucleoli, speckles, Cajal bodies, and promyelocytic leukemia nuclear bodies
(PML NBs) [6,7]. While the structure and function of nucleoli, which is mainly riboso-
mal RNA synthesis and ribosome biogenesis, is very well understood, the precise bio-
chemical function of speckles, Cajal bodies or PML nuclear bodies is not known [6].
With the exception, again, of the nucleolus which builds on ribosomal RNA genes, it
also remains elusive if and how the other nuclear domains are spatially and
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to specific genomic regions [7].
PML nuclear bodies, also known as nuclear domain 10 (ND10) are macromolecular
protein assemblies in the nucleus of mammalian cells. They have been implicated in
key cellular functions including cell cycle progression, the DNA damage response,
transcriptional regulation, viral infection, and apoptosis, however the precise biochem-
i c a lf u n c t i o n so fP M LN B si nt h e s ep r o c e s s e si sn o tk n o w n[ 8 , 9 ] .P M LN B sr a n g ei n
size from 0.2 μmt o1 . 2μm in diameter [10]. The number and distribution of PML
NBs varies considerably depending on cell type, cell cycle and cell condition, but typi-
cally between 10 and 20 PML NBs can be found per nucleus [11]. Electron and 4Pi-
microscopy revealed a ring-like shape of PML NBs under normal growth conditions
with an 50 to 100 nm thick proteinacous outer shell [10]. The core of PML NBs was
found either free of protein, DNA, or RNA accumulations [10-12], or to contain speci-
fic SUMO isoforms or specific chromatin subregions [10]. Chromatin threads and
RNA in direct contact with the surface of the bodies might help to stabilize nuclear
body structure [13,14].
T h es i g n a t u r ep r o t e i no fP M LN B si st h epromyelocytic leukemia gene product
because PML-negative cells are unable to form nuclear bodies and other PML NB
components show a dispersed nuclear distribution [15]. Six nuclear PML isoforms
which vary in their carboxy termini are expressed by alternative splicing of the PML
gene in humans (Fig. 1A) [16,17]. PML proteins may exert their isoform-specific func-
tions through interaction with specific protein partners at nuclear bodies or within
chromatin away from the bodies, or both [8]. Proteins present at PML NBs at endo-
genous expression levels include Sp100, Daxx, the Bloom’ss y n d r o m eg e n ep r o d u c t
(BLM), the small ubiquitin-related modifier 1-3 (SUMO1-3), and NDP 55 [18].
The formation of PML nuclear bodies relies primarily on the self-assembly abilities
of the N-terminal RBCC domain in PML, and its SUMOylation status [15,19,20]. PML
as well as other PML NB components, such as Sp100 and Daxx contain a SUMO
interacting motif (SIM) with which these proteins can bind SUMO noncovalently [21].
Binding of proteins to PML nuclear bodies can therefore be modulated by noncovalent
interactions between the SUMO moieties and SIMs of PML-interacting components
[22,23].
PML nuclear bodies may be directly involved in biochemical reactions in the cell
nucleus by modulating chromatin structure, regulating transcription of specific genes,
sequestering of specific nuclear proteins, and/or mediating posttranslational modifica-
tions of specific target proteins [8]. Inherent to all these models is the question if PML
NB components function directly within this structure or somewhere outside at differ-
ent intra-nuclear sites, or both. A regulated network traffic between these sites may
constitute a potential control mechanism with PML at its core, as suggested very early
[24].
In order to reveal and study such mechanisms we have previously assessed the bio-
physical properties of PML nuclear body components and the assembly dynamics of
these macromolecular domains in nuclei of living human cells using fluorescence cor-
relation spectroscopy, fluorescence recovery after photobleaching and mathematic
modeling [25]. These analyses uncovered a kinetic model for factor exchange at PML
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Page 2 of 15Figure 1 All PML protein isoforms form nuclear bodies in cells lacking endogenous PML.
(A) Schematic depiction of the domain structure of PML isoforms (data taken from [16]). All PML isoforms
share a common N terminus (exons 1 to 6) but differ in their C termini due to alternative spilicing of
exons 7 to 9. Numbers indicate exons. Stars indicate retained intron sequences. The postion of three
SUMO-modifyable Lysin (K) residues are indicated. Note that PML VI does not contain and the SUMO-
interacting motiv (SIM) present in the other isoforms. (B) Mouse 3T3 cells with (3T3-PML
+/+) or without
(3T3-PML
-/-) endogenous PML expression were transfested with expression vectors encoding human PML
isoforms I to VI as GFP fusion proteins. Cells on coverslips were fixed and processed for
immunofluorescence staining to detect endogenous mouse PML protein (red) and the exogenous
GFP-tagged human PML isoforms (green). Images show mid-nuclear confocal sections. Note that the
anti-mouse-PML antibody does not cross-react with human PML. Bar, 5 μm.
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ing of PML NB components. To further characterize the assembly of PML nuclear
bodies we now performed biophysical analyses in living mouse cells lacking endogen-
ous PML proteins. This allowed us to study the nuclear body formation abilities of
individual PML isoforms in a live cell setting.
2 Methods
Cell Culture and Transfection
Mouse 3T3-PML
+/+ and 3T3-PML
-/- cells [26], kindly provided by T. Hofmann (DKFZ
Heidelberg) were cultured in Dulbecco’ modified Eagle’s medium (DMEM) supplemen-
ted with 10% fetal calf serum in a 10% CO2 atmosphere at 37°C. For live cell imaging
experiments, cells were seeded on 42 mm glass dishes (Saur Laborbedarf, Reutlingen,
Germany) and transfected with plasmid DNA one to two days before observation
using FuGENE-HD Transfection reagent (Roche, Basel, Switzerland) according to the
manufacturer’ protocol.
Plasmids
The GFP-PML expression constructs have been described in detail previously [25].
Western blots
Whole cell extracts were produced from transiently or stably transfected cell lines,
electrophoresed on SDS-PAGE and transferred to Protran nitrocellulose membrane
(Schleicher & Schuell, Dassel, Germany). The membrane was incubated with primary
antibodies (in PBS-T) and developed with a peroxidase conjugated secondary spe-
cies-specific antibody (Jackson Immunoresearch, West Grove, PA, USA). Signal was
detected using the ECL reagent (Amersham, Uppsala, Sweden) on imaging film (Bio-
max, Kodak, Stuttgart, Germany). Anti-GFP monoclonal antibody was from Santa-
Cruz Biotechnology (Heidelberg, Germany). Anti-mouse PML monoclonal antibody
(# 05-718), non-cross reactive with human PML protein, was purchased from
Upstate.
Immunocytochemistry and Microscopy
Cells grown on 15 mm diameter coverslips were fixed with 4% formaldehyde for 10
minutes and permeabilized with 0.25% Triton-X100 for 3 minutes. Diluted anti-mouse
PML mAB was incubated on cells for 45 minutes. After 3 washing steps with PBS, an
anti-mouse secondary antibody coupled to Cy3 (Jackson Immunosearch, West Grove,
USA) was incubated on cells for 45 minutes, followed by a DNA-staining step using
ToPro3 or DAPI (Invitrogen, Carlsbad, USA) for 10 minutes and mounting with Pro-
long Gold antifade mounting medium (Invitrogen, Carlsbad, USA). For microscopy,
a LSM 510Meta or LSM710 laser scanning confocal microscope (Carl Zeiss, Jena,
Germany) was used.
Fluorescence Correlation Spectroscopy Measurements
Fluorescence correlation spectroscopy (FCS) measurements were performed at 37°C on
a LSM 510Meta/ConfoCor2 combi system using a C-Apochromat infinity-corrected
1.2 NA 40× water objective (Carl Zeiss, Jena, Germany) as described in detail
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line of a 20 mW Argon laser at 5.5 Ampere tube current attenuated by an acousto-
optical tunable filter (AOTF) to 0.1%. The detection pinhole had a diameter of 70 μm
and emission was recorded through a 505-530 nm band-path filter. For the measur-
ments, 10 × 30 time series of 10 s each were recorded with a time resolution of 1 μs
a n dt h e ns u p e r i m p o s e df o rf i t t i n gt oa na n o malous diffusion model in three dimen-
sions with triplett function [27] using Origin Software (OriginLab, Northhampton,
MA, USA). The diffusion coefficients and anomaly parameters were extracted from fit
curves as previously described [25].
Fluorescence Recovery after Photobleaching
Fluorescence Recovery after Photobleaching (FRAP) experiments were carried out on a
Zeiss LSM 510Meta confocal microscope (Carl Zeiss, Jena, Germany). One or two
image stacks were taken before the bleach pulse and 50-70 image stacks after bleaching
of “regions of interest” (ROIs) containing one nuclear body each at 0.05% laser trans-
mission to minimize scan bleaching. Image aquisition frequency was adapted to the
recovery rate of the respective GFP fusion protein, usually a 20 second interval was
applied. The pinhole was adjusted to 1 airy unit. The image stacks were maximum-
projected into a single plane from which relative fluorescence intensities within the
ROIs were quantitated according to [25] using Excel (Microsoft, Redmond, WA, USA)
and Origin software (OriginLab, Northhampton, MA, USA).
Reaction-diffusion model
For the mathematical model, the structural complexity of a PML body has been
approximated assuming that molecules undergoing binding and unbinding to and
from the body do so at the surface, and molecules situated more towards the inside of
the body cannot unbind before moving to the surface. There is thus a reservoir of
tightly bound “inner” molecules and one of loosely bound “outer” ones. Exchange
between these reservoirs is modeled by linear kinetics, i. e. the more molecules there
a r e ,t h em o r ew i l lm o v ei n s i d eo ro u tw i t hr a t ec o n s t a n t skin and kout, respectively.
Binding and unbinding to the PML body is treated similarly, with rate constants kon
and koff, respectively. The experimental set-up provided that bleach ROI and FRAP
ROI is similar, and so are assumed to be the same for modelling purposes. Diffusion
inside and out of the ROI was modelled as a linear two-way process with a rate con-
stant proportional 2D/r
2, where D is the diffusion coefficient measured by FCS, and r
is the ROI’s radius. This constant yields the effective exchange rate through the
boundary of a circular area. The model considers only fluorescent molecules of one
type at a time, so no interactions between different molecular species are considered.
It distinguishes between molecules outside the ROI, inside the ROI but diffusing
freely, loosely bound at the surface of the PML body, and tightly bound inside the
body. The fluorescence outside the ROI is all but unchanged by the bleaching pulse
and subsequent diffusion, so this value was used to normalize all concentrations in the
equations. Describing normalized concentrations of the fluorescent protein in free dif-
fusion (x), loosely bound (y) and tightly bound (z), the reaction system results in the
model equations
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The differential equations were numerically solved using an explicit Runge-Kutta for-
mula (method ode45 in MATLAB). To fit the parameters of the model, an Evolution
Strategy with Covariance Matrix Adaptation (CMA-ES) was employed [28].
We determined the ratio p = 20 of steady state fluorescence in the body vs. the back-
ground by confocal microscopy of GFP-PML isoforms and pixel intensity evaluation
using MetaMorph software (Molecular Devices, Sunnyvale, USA).
This enabled us to express the observable fluorescence in the ROI as
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Since the amount of bleached molecules is small compared to the overall amount of
molecules in the nucleus, it is plausible to assume that after a sufficiently long time,
fluorescence returns to the value measured before the photobleach. This constraint
removes one degree of freedom from the model, yielding
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T h e s ev a l u e sw e r eu s e dt on o r m a l i z et h ec o n c e n t r a t i o n su s e di nt h em o d e l .T h e
mathematical model treats normalized concentrations of fluorescent molecules in free
diffusion (x), loosely bound (y) and tightly bound (z) to the PML body.
It is important to note that the concentration values x, y and z have been normalized
by the background fluorescence outside the region of interest. Since we have deter-
mined the ratio p between equilibrium fluorescence inside the body and outside the
ROI, and because the data used to fit the model was given in relative fluorescence
intensity with an equilibrium value of 1, the background flourescence is given by 1/p.
Therefore, the observed RFI value w is related to the model concentrations by
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p
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Over a very long time, all molecular species in the PML-body will eventually turn over,
so that it is reasonable to assume w(t) tends towards 1 for large t. This means that for
equilibrium conditions, in which dx
dt
dy
dt
dz
dt  0 , w(t) = 1. In this case, we have
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Finally, taking this together with the conditition x+y+z= p, we find
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This enabled us to remove one degree of freedom, kon, from the model.
3 Results and Discussion
3.1 All PML isoforms form nuclear bodies in PML-/- cells
W eh a dp r e v i o u s l ya n a l y z e dt h ed y n a m i cs of component exchange at PML nuclear
bodies in human cells expressing endogenous PML proteins [25]. The objective of the
current study was to study the formation of PML NBs in the absence of endogenous
PML expression. All six human PML isoforms (Fig. 1A) were therefore expressed as
GFP fusion proteins in mouse 3T3 control cells (3T3-PML
+/+)o rm o u s e3 T 3c e l l s
derived from PML knock-out mice (3T3-PML
-/-). All GFP-PML constructs are func-
tional in human cells [25] and were expressed as full-length proteins in 3T3 cells, as
judged by western-blotting (data not shown).
Immunofluorescence analyses showed that all six human GFP-PML isoforms loca-
lized to enogenous PML nuclear bodies in 3T3-PML
+/+ mouse cells (Fig. 1B). Impor-
tantly, in 3T3-PML
-/- mouse cells, each individual human GFP-PML isoform was able
to form nuclear bodies (Fig. 1B). This confirmed that the nuclear body formation abil-
ity of PML resides within sequences encoded by exons 1 to 6, represented by GFP-
PML VI, and suggests that the C-terminal extensions of PML isoforms (exons 7 to 9)
do not alter this function (Fig. 1B). Because GFP-PML VI which does not contain the
SUMO-interacting motiv (SIM) (Fig. 1A) is still able to form nuclear bodies in the
absence of endogenous PML bodies we conclude that a SIM is not essential for nuclear
body formation by PML as previously suggested [22].
3.2 PML isoform specific binding properties at nuclear bodies
To study the binding properties of individual PML isoforms at nuclear bodies we
employed FRAP. A spherical region containing one PML nuclear body was bleached to
background levels and fluorescence recovery was monitored for 20 min (Fig. 2). Similar
to human cells [25], all six GFP-PML isoforms exhibited protein-specific FRAP curves
in 3T3 cells expressing endogenous PML nuclear bodies (Fig. 3, black curves). In parti-
cular, we could confirm that exchange of GFP-PML V is extremely slow: fluorescence
recovered to only ~40% after 20 min indicating a very slow turn over of PML V
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clusion that PML V may act as a hyper-stable scaffold component within PML nuclear
bodies [25].
Human cells contain six nuclear PML isoforms, whereas for mouse cells only two
PML transcripts have been described so far, and the corrsponding mouse PML
sequences are more than 80% similar to human PML isoform I [29]. It should there-
fore be pointed out that PML isoforms II to VI have no direct counterparts in the
murine system with respect to alternative expression of exons 6 to 9. Nevertheless, the
analysis of these human isoforms in mouse cells may still deliver valuable information
Figure 2 FRAP to determine exchange of PML isoforms at nuclear bodies. (A) FRAP experiment of
GFP-tagged PML II in 3T3-PML
+/+ cells. Fluorescence was bleached in circled areas containing a nuclear
body as indicated. Image stacks of the whole nucleus were taken before (pre) and after (post) the bleach
pulse and at different time points thereafter. The upper row shows the projection of the whole nucleus
while the bottom row shows an enlarged view of the bleached nuclear body indicated by a white box.
(B and C) Same experiment as in (A) using 3T3-PML
-/- cells. In one cell population fluorescence recovery
was observed with kinetics similar to PML wild type cells (B) while in another fraction of cells no recovery
of GFP-PML II at nuclear bodies was oberved (C). Bar, 5 μm.
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the high sequence similarity the human GFP-PML I construct has the potential to
functionally (and thus dynamically) act in a similar fashion as mouse PML in murine
cells. Indeed, the exchange dynamics of human GFP-PML I protein at nuclear bodies
of PML-positive murine cells was similar to human cells (Fig. 3A) [25]. In contrast,
GFP-PML I was alomst immobile at nuclear bodies in 3T3 cells lacking endogenous
PML (Fig. 3A). The same phenomenon was observed for GFP-PML isoform III and in
a subpopulation of cells expressing GFP-PML isoforms II or IV (Fig. 3, B-D). Thus, in
the absence of endogenous PML proteins, GFP-PML I to IV form stable aggregates.
These observations suggest that these isoforms require the presence of other PML iso-
forms or endogenous PML-binding proteins for efficient exchange at nuclear bodies.
They also suggest that the capacity to contribute to nuclear body stability is inherent
Figure 3 Quantitation of FRAP experiments. FRAP experiments as described in Figure 2 were performed
for all GFP-PML isoforms in PML positive (black curves) and PML negative cells (red curves) as indicated. A
second mobility population of PML negative cells was observed for GFP-PML II and IV (blue curves). The
graphs show the mean values from at least 20 FRAP evaluations as relative fluorescence intensity (RFI) after
normalization to prebleach levels. Standart deviations (not shown) ranged between 10 to 15 percent of the
mean values.
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which GFP-PML isoforms II and IV showed dynamic exchange at nuclear bodies (Fig.
3B, and 3D, red curves). These observations suggest a cell cycle dependent behavior of
PML II and PML IV at nuclear bodies which likely originate from interaction of these
isoforms with as yet unknown binding sites outside nuclear bodies. However, since
human PML II and PML IV are not conserved in mouse cells, such interactions might
be biologically non-relevant. In contrast to GFP-PML I to IV, the dynamics of GFP-
PML V and VI were almost unaltered in PML negative cells (Fig. 3E, and 3F).
The presence of slow exchanging populations of GFP-PML I to IV is consistent with
the idea that these isoforms are also able to provide nuclear body stability, as con-
cluded for PML V. In human cells, GFP-PML I and III exhibit much higher exchange
rates at nuclear bodies [25] than observed here in mouse cells (Fig. 3).
That GFP-PML I and III do not exchange with soluble nucleoplasmic populations in
mouse cells may indicate that the human isoforms can not be dissociated from nuclear
bodies through interaction with soluble mouse PML-binding proteins outside nuclear
bodies. Since the SUMOylation status of PML also regulates the exchange rate at
nuclear bodies [25], changing SUMO patterns on GFP-PML I to IV may also explain
their changing exchange rate at NBs.
3.3 A kinetic model to quantitatively describe PML nuclear body assembly
In order to understand PML nuclear body assembly in a more quantitative way we
applied a kinetic modeling approach established previously [25] (Fig. 4A). Diffusion
inside and out of bleached regions was modelled as a linear two-way process as
described in the materials and methods section. The diffusion coefficients of the GFP-
PML isoforms, as determined by fluorescence correlation spectroscopy, ranged between
D=1-3μm
2s
-1 (data not shown). Table 1 contains for each of the PML protein iso-
forms the binding and unbinding rate kon and koff,a n dt h er a t eo fm o v e m e n tt ot h e
inner core and to the outer surface of the body, kin and kout. From these, we computed
the residence time (R.t.), i.e. the mean time a molecule spends bound to the nuclear
body, and the fraction of molecules bound in the inner and outer region of the body,
bndin and bndout. This model provided good fits to the measured FRAP curves of all
PML isoforms (Fig. 4, B-O). This quantitative evaluation confirmed that GFP-PML V
had the longest residence time (947 s) of all isoforms in PML-positive cells (Table 1).
The residence times of GFP-PML isoforms I to IV ranged between 221 and 336 sec-
onds which is very similar to their residence times at nuclear bodies in human cells
[25]. Thus, each PML isoform exhibits individual exchange characteristcs at nuclear
bodies. Since the molecular structure of PML isoforms are identical over two-thirds of
the sequence at the N-termiuns, the observed differences in the dynamic behaviour
must originate from their C-terminal varying parts.
Compared to PML-positive cells, the residence time at nuclear bodies of GFP-tagged
PML isoforms I to IV was increased several-fold in PML-negative cells (Table 1). This
result suggests that the exchange rate of overexpressed human PML isoforms is influ-
enced by the dynamics of the endogenous mouse PML proteins. Thus, in the absence
of endogenous mouse PML protein, the unrelated human isoforms tend to form more
insoluble aggregates. Interestingly, this is not true for the shortest PML isoforms V
and VI, the residence time of which is almost identical independent of the presence or
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and VI argues in favor of a more structural role for these isoforms at PML nuclear
bodies.
3.4 SUMOylation of PML is required to form nuclear bodies
PML contains three Lysine residues (K65, K160, and K490; Fig. 1A) at which all iso-
forms can be SUMOylated in vivo [30]. To determine the impact of SUMO
Figure 4 Kinetic model for molecule exchange at PML nuclear bodies. (A) Molecules with the
potential to interact with PML nuclear bodies move by diffusion in the nucleoplasm outside nuclear
bodies. Upon stochastic encounter, molecules associate and dissociate from the periphery of the nuclear
body (kon and koff, respectively) and penetrate into and out of the shell of the nuclear body (kin and kout,
respectively). (B-O) Fitting of the measured FRAP curves (blue dotted line) with the binding-diffusion model
shown in (A) results in good fits (red lines).
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in which K160 and K490 were mutated to Arginine. This mutant protein localized dif-
fusely in the nucleoplasm of both PML-positive and PML-negative cells (Fig. 5, and
data not shown) indicating that SUMOylation at K160 and K490 are required for PML
nuclear body binding. FRAP analysis of the SUMO mutant within a nucleoplasmic
region revealed fast and complete recovery within seconds suggesting a predominant
diffusion type of mobility (Fig. 5). We had shown previously that the K160/490R
mutant is still able to bind to nuclear bodies in human cells but its residence time was
only 5.8 s compared to the residence time of wild-type GFP-PML IV, which is 7.6 min
[25]. Thus, the human K160/490R mutant very transiently interacts at ‘human’ PML
bodies [25] but does not bind to ‘mouse’ PML bodies and is not able to form nuclear
body structures in the absence of any PML protein (Fig. 5). Bacterially expressed PML
protein is not SUMO-modified but still able to form nuclear body-like structures in
vitro through self-assembly of the N-terminal RBCC region of PML [31]. Because GFP-
PML-K160/490R is not able to form nuclear body structures in the absence of other
mouse or human PML proteins (Fig. 5) we conclude that SUMOylation is a critical
determinant for PML body formation. In future studies it will be intersting to analyze
the impact of single, double and the triple SUMO mutants of PML in nuclear body
formation.
3.5 Assembly properties of PML bodies are different from other subnuclear domains
FRAP analyses of subnuclear domains such as speckles, Cajal bodies and nucleoli had
revealed that their component parts rapidly exchange with nucleoplasmic pools
[32-39]. Typical residence times of proteins within these compartments are in the sec-
onds range (Fig. 6). These observations have led to the conclusion that nuclear body
proteins undergo repeated and rapid cycles of association and dissociation between the
nuclear body and the nucleoplasm [40]. As a consequence, a nuclear body is in
Table 1 Exchange dynamics of PML isoforms at nuclear bodies
Protein Cells kon(s
-1) koff(s
-1) kin(s
-1) kout(s
-1) R.t. (s) bndout bndin
GFP-PML I PML
+/+ 0.0633 0.0051 0.0002 0.0004 300 0.65 0.35
GFP-PML I PML
-/- 0.0015 0.0015 >0.0001 0.0049 648 1.00 0.00
GFP-PML II PML
+/+ 0.0856 0.0069 >0.0001 >0.0001 222 0.65 0.35
GFP-PML II
immob PML
-/- 0.0000 n.d. n.d. n.d. n.d. n.d. n.d.
GFP-PML II
mob PML
-/- 0.0288 0.0031 >0.0001 >0.0001 659 0.49 0.51
GFP-PML III PML
+/+ 0.0692 0.0055 >0.0001 0.0007 274 0.67 0.33
GFP-PML III PML
-/- 0.0023 0.0013 >0.0001 0.5592 744 1.00 0.00
GFP-PML IV PML
+/+ 0.0565 0.0034 >0.0001 >0.0001 337 0.87 0.13
GFP-PML IV
immob PML
-/- 0.0040 0.0005 >0.0001 >0.0001 4777 0.38 0.62
GFP-PML IV
mob PML
-/- 0.0571 0.0037 >0.0001 >0.0001 333 0.81 0.19
GFP-PML V PML
+/+ 0.0199 0.0024 >0.0001 >0.0001 957 0.43 0.57
GFP-PML V PML
-/- 0.0188 0.0016 >0.0001 >0.0001 1010 0.61 0.39
GFP-PML VI PML
+/+ 0.0351 0.0021 >0.0001 >0.0001 541 0.90 0.10
GFP-PML VI PML
-/- 0.0385 0.0036 0.0008 0.0010 493 0.56 0.44
The diffusion-binding model described in Figure 4A was used to extract kinetic data from the FRAP and FCS
experiments for all PML isoforms in PML positive and PML negative cells. kon: association rate at the surface of the
nuclear body; koff: dissociation rate at the surface of the nuclear body; kin: penetration rate into the nuclear body; kout:
penetration rate out of the core of the nuclear body; R.t.: mean residence time at nuclear bodies; bndout: fraction of
molecules residing at the surface of the nuclear body; bndin: fraction of molecules residing in the core of the nuclear
body.
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Page 12 of 15Figure 5 PML SUMOylation sites K160 and K490 are required for PML body formation. The upper
part shows a FRAP experiment of GFP-tagged mutant PML IV (K160/490R) in 3T3-PML
-/- cells. Fluorescence
was bleached in a circled area within the nucleoplasm (red circle). Confocal images were taken before (pre)
and after (post) the bleach pulse and at different time points thereafter. Bottom part: FRAP experiments of
GFP-tagged PML IV (K160/490R) were performed in 3T3-PML
+/+ (black) and 3T3-PML
-/- cells (red) and
quantified. FRAP curves show mean values of at least ten measurements.
Figure 6 Assembly dynamics of subnuclear domains. The residence times of components of the
indicated subnuclear domains are depicted on a logarithmic scale between 1 second and 1 hour. Fast or
slow exchanging components provide flexibility or stabilty, respectively, probably in terms of both structue
and function of subnuclear domains. Residence times of speckle, nucleolus and Cajal body compoents
were assessed from FRAP experiments published previously [32-39]. Residence times of PML nuclear body
components were taken from [25].
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Page 13 of 15perpetual flux and its structure is determined by the ratio of on-rate versus off-rate of
its components [41]. While this assembly mechanism is certainly true for speckles,
Cajal bodies and nucleoli, the work presented here and previously [25] demonstrate
that the stabilty of PML nuclear bodies relies on very long residence times of specific
PML isoforms, in particular PML V [25] (Fig. 6), and probably also PML VI (Table 1).
These observations strongly support the idea of a scaffold function of PML nuclear
bodies [42].
4 Conclusions
Four main mechanisms are known through which cellular scaffolds can modify signal-
ling between active components [43]. They can (i) tether enzymes close in space and
enhance effective local concentrations, (ii) mediate assembly of signalling complexes in
a combinatorial manner, (iii) dynamically regulate turnover or accessibility of specific
factors, or (iv) modify the conformation of enzymes binding to them [43]. All these
potential functions are fully compatible with the biophysical properties of PML nuclear
bodies assessed in this report and previously [25]. The scaffold model for PML body
function is also compatible with the biochemistry (phosphorylation, SUMOylation,
acetylation) believed to occur on specific nuclear proteins at these macromolecular
assemblies [8]. Interestingly, although direct evidence is lacking so far, PML NBs have
recently been suggested as scaffolds for caspase-2 mediated cell death [44]. Future
research should therefore aim to establish new experimental approaches with which
the potential function of PML nuclear bodies as nuclear scaffolds can be tested in a
more direct and functional way.
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